AMRN: Amarin Corporation plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMRN: Amarin Corporation plc

AMRN 16.29

-0.7%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: ariadough	6/12/2012 9:32:59 AM
	of 49

Canaccord Genuity reiterates a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $25.00. Analyst, Ritu Baral, said, "Reiterates rating and price target on AMR101 commercial, partnering potential. We think AMR101, Amarin's 96% EPA omega-3, will be approved for hypertriglyceridemia in H2/12, likely around its July 26 PDUFA date, with a broad label that will include ANCHOR trial mixed dyslipidemia data. We expect additional IP and business development progress in H2/12." "We strongly believe AMR101 will be approved soon. We see the AMR101 clinical/CMC package as strong. Based on FOIA feedback, we think no new AMR101 plant inspections were needed for CMC." For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarain Corporation click here.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next